Breast Cancer Clinical Trial
Official title:
Breast Cancer Prevention by Inducing Apoptosis in DCIS Using Breast Ductal Lavage
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help
doctors learn more about changes that occur in DNA and identify biomarkers related to
cancer.
PURPOSE: This laboratory study is evaluating cells collected through ductal lavage in women
undergoing surgery for ductal carcinoma in situ or other breast cancer.
OBJECTIVES:
- Determine the expression pattern of the programmed cell death (PCD) regulatory genes
bcl-2, bax, and bcl-xL in primary ductal carcinoma in situ (DCIS) cultures.
- Determine whether down-regulation by genetic manipulation of the anti-apoptotic genes
bcl-2 and/or bcl-xL, alone or in conjunction with physiological preventive doses of
tamoxifen citrate, has the highest induction of PCD in primary DCIS cell cultures.
- Determine the expression pattern of the PCD regulatory genes bcl-2, bax, and bcl-xL in
cells obtained by breast ductal lavage.
- Determine whether down-regulation by genetic manipulation of the anti-apoptotic genes
bcl-2 and/or bcl-xL, alone or in conjunction with physiological preventive doses of
tamoxifen citrate, has the highest induction of PCD in cells obtained by breast ductal
lavage.
OUTLINE: Patients undergo breast lavage to collect primary epithelial cells for cytological
analysis before a planned surgical procedure. Ductal carcinoma in situ (DCIS) tissue samples
obtained from surgery are used to establish primary DCIS cell cultures. The DCIS cells and
primary epithelial cells obtained by ductal lavage are analyzed for endogenous protein
levels of bcl-2, bax, and bcl-xL, using western blotting and immunohistochemical staining,
to determine the appropriate antisense oligonucleotide molecule that will be used to induce
apoptosis. The DCIS cells and primary epithelial cells obtained by ductal lavage are treated
with antisense oligonucleotides and/or a physiological chemopreventive dose of tamoxifen
citrate to determine which will provide the highest induction of cell death. The effect of
these treatments on protein expression is analyzed by western blotting and
immunohistochemistry. The effect of these treatments on markers of programed cell death
(PCD) (i.e., DNA fragmentation and caspase activation) is also analyzed. Changes in mRNA
expression are analyzed using a PCR-based quantitation assay.
Results from the molecular marker assays are not provided to the patients.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
| Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |